Výsledky vyhledávání - "Ewa Karwatowska‑Prokopczuk"

Akademický článek

Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans

Autor: Ewa Karwatowska-Prokopczuk, Anastasia Lesogor, Jing-He Yan, Angelika Hoenlinger, Alison Margolskee, Lu Li, Sotirios Tsimikas

Publikováno v: Lipids in Health and Disease, Vol 23, Iss 1, Pp 1-12 (2024)

Abstract Background Olezarsen is a GalNAc3-conjugated, hepatic-targeted antisense oligonucleotide that lowers apolipoprotein C-III (apoC-III) and triglyceride levels. The efficacy and safety of olezarsen has not previously been studied in ethnically

Externí odkaz: https://doaj.org/article/2e72f091741646ae9beffefe9a32d9df

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF OLEZARSEN IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME: THE BALANCE TRIAL

Autor: Ewa Karwatowska-Prokopczuk, MD, PhD

Publikováno v: American Journal of Preventive Cardiology, Vol 19, Iss , Pp 100854- (2024)

Therapeutic Area: Pharmacologic Therapy Background: Familial chylomicronemia syndrome (FCS) is a rare genetic disorder of lipoprotein lipase deficiency that results in severe hypertriglyceridemia and an increased risk of potentially life-threatening

Externí odkaz: https://doaj.org/article/094ff595f80745b1b9d50668d19a568c

Zobrazit plný text záznamu

Akademický článek

Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study

Autor: Maria C. Foss-Freitas, Baris Akinci, Adam Neidert, Victoria J. Bartlett, Eunju Hurh, Ewa Karwatowska-Prokopczuk, Elif A. Oral

Publikováno v: Lipids in Health and Disease, Vol 20, Iss 1, Pp 1-12 (2021)

Abstract Background Familial partial lipodystrophy (FPLD) is a rare disease characterized by selective loss of peripheral subcutaneous fat, associated with dyslipidemia and diabetes mellitus. Reductions in circulating levels of ANGPTL3 are associated

Externí odkaz: https://doaj.org/article/50ffdd79d6e14f6093c4b51acb7bcb51

Zobrazit plný text záznamu

Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects

Autor: Ewa Karwatowska‑Prokopczuk, Anastasia Lesogor, Jing-He Yan, Eunju Hurh, Angelika Hoenlinger, Alison Margolskee, Shuting Xia, Sotirios Tsimikas

Publikováno v: Journal of Clinical Lipidology. 17:181-188

Pelacarsen is a liver-targeted antisense oligonucleotide that potently lowers lipoprotein(a) [Lp(a)] levels. Its safety and efficacy in diverse populations has not been extensively studied.To assess the effect of pelacarsen, including monthly dosing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::881353bc28a966e5c7705b04cba83629
https://doi.org/10.1016/j.jacl.2022.12.001

Zobrazit plný text záznamu

Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia

Autor: Ewa Karwatowska-Prokopczuk, Jean-Claude Tardif, Daniel Gaudet, Christie M. Ballantyne, Michael D. Shapiro, Patrick M. Moriarty, Seth J. Baum, Eric St Amour, Veronica J. Alexander, Shuting Xia, James D. Otvos, Joseph L. Witztum, Sotirios Tsimikas

Publikováno v: Journal of Clinical Lipidology. 16:617-625

Olezarsen is a hepatocyte-targeted, GalNAc-modified antisense oligonucleotide that decreases plasma levels of apolipoprotein C-III (apoC-III) and triglyceride-rich lipoproteins (TRLs).To define the effect of olezarsen on NMR-derived lipoprotein parti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68a1a318ab7ac2a72462312d99c8a5ad
https://doi.org/10.1016/j.jacl.2022.06.005

Zobrazit plný text záznamu

Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study

Autor: Victoria J Bartlett, Eunju Hurh, Elif Arioglu Oral, Adam H. Neidert, Ewa Karwatowska-Prokopczuk, Baris Akinci, Maria C Foss-Freitas

Publikováno v: Lipids in Health and Disease, Vol 20, Iss 1, Pp 1-12 (2021)
Lipids in Health and Disease

Background Familial partial lipodystrophy (FPLD) is a rare disease characterized by selective loss of peripheral subcutaneous fat, associated with dyslipidemia and diabetes mellitus. Reductions in circulating levels of ANGPTL3 are associated with low

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c02b87ec1f624c5136d88267c15fe1e
https://doaj.org/article/50ffdd79d6e14f6093c4b51acb7bcb51

Zobrazit plný text záznamu

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Autor: Jean-Claude Tardif, Ewa Karwatowska-Prokopczuk, Eric St Amour, Christie M Ballantyne, Michael D Shapiro, Patrick M Moriarty, Seth J Baum, Eunju Hurh, Victoria J Bartlett, Joyce Kingsbury, Amparo L Figueroa, Veronica J Alexander, Joseph Tami, Joseph L Witztum, Richard S Geary, Louis St L O’Dea, Sotirios Tsimikas, Daniel Gaudet

Publikováno v: European heart journal, vol 43, iss 14

Aims Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ab435f70ddb9874ac3d5d38b0c089f7
https://escholarship.org/uc/item/52k3p81s

Zobrazit plný text záznamu

Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2'-MOE and Phosphorothioate Modified Antisense Oligonucleotides

Autor: Yanfeng Wang, John K. Diep, Rosie Z. Yu, Eunju Hurh, Ewa Karwatowska‐Prokopczuk, Eugene Schneider, Scott Henry, Sanjay Bhanot, Richard S. Geary

Publikováno v: Journal of clinical pharmacologyReferences.

The pharmacokinetics (PK) of 2'-O-methoxyethyl and phosphorothioate antisense oligonucleotides (ASOs), with or without N-acetyl galactosamine conjugation, have been well characterized following subcutaneous or intravenous drug administration. However

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60c46dc27f55a183d4b9afa6f7b0ecf
https://pubmed.ncbi.nlm.nih.gov/35801818

Zobrazit plný text záznamu

Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide TargetingAPOC3mRNA, Does Not Affect the QTc Interval in Healthy Volunteers

Autor: Louis O'Dea, Richard S. Geary, Eunju Hurh, Veronica J. Alexander, Kristin Balogh, Lynnetta Watts, Ewa Karwatowska-Prokopczuk, Sotirios Tsimikas

Publikováno v: Nucleic Acid Therapeutics. 30:198-206

The aim of this study was to assess the effect of volanesorsen on the corrected QT (QTc) interval. This thorough QT study enrolled 52 healthy male and female subjects who were randomized at a singl...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d58d2ba6edce51833df1ea253692149
https://doi.org/10.1089/nat.2019.0837

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání